Clinical trials: CtDNA
Unresectable Metastatic Melanoma
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable…
- Trial name
- BRAF SENS (NCT07870265)
- Testing
- Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripheral Blood Sampling for Liquid Biopsy
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Masaryk Memorial Cancer Institute
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER
Cancer of the Lung, Lung Cancer
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
Patients who are about to undergo a diagnostic or therapeutic bronchoscopy or thoracic surgery without a distant history of cancer will have their blood drawn for measurement of circulating tumor DNA (ctDNA) to validate the…
- Conditions
- Cancer of the Lung, Lung Cancer, Lung Neoplasms, Adenocarcinoma of the Lung
- Trial name
- NCT02715102
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Pathway Genomics
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Carcinoma, Non-small-cell Lung Cancer
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02696525
- Where
- 3 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM)
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA)
- Trial name
- ctDNA TAP (NCT07310537)
- Testing
- Blood Collection - TAP® Device, Blood Collection - Venous
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Pancreatic Cancer
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
This study aims to conduct a large-scale prospective clinical trial to evaluate the efficacy and safety of capecitabine monotherapy as maintenance treatment following standard adjuvant chemotherapy (gemcitabine plus capecitabine)…
- Trial name
- NCT07054879
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostatic Neoplasms
Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer
In this project, we would like to focus on castration-sensitive prostate cancer (CRPC). This is a highly variable clinical picture with differentiated and burdening symptoms.
- Trial name
- NCT03677414
- Where
- Austria
- Volunteers
- 59 people
- Sponsor
- Medical University of Graz
Testicular Germ Cell Tumor
Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment
1. To establish whether circulating tumour DNA is detectable in the plasma of patients with platinum refractory/resistant Germ Cell Tumours 2. If ctDNA is detectable, perform exploratory analyses to: 1.
- Trial name
- EMIT (NCT03980587)
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Royal Marsden NHS Foundation Trust
ctDNA, Gastric Cancer
Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma
This is a single-center, prospective, exploratory study evaluating the use of dynamic circulating tumor DNA (ctDNA) monitoring in the postoperative adjuvant treatment setting for patients with stage III or stage IVA gastric or…
- Conditions
- ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Adjuvant Treatment
- Trial name
- NCT07507916
- Testing
- HLX10, SOX Chemotherapy
- Volunteers
- 32 people
- Sponsor
- Fudan University
Colon Cancer
ctDNA and TEP Levels in Colon Cancer
This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic…
- Trial name
- NCT07701408
- Testing
- Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis
- Where
- Slovenia
- Volunteers
- 80 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Neoplasm
Prognostic Value of Circulating Tumor DNA Dosing in Patients in Neoadjuvant Breast Neoplasia
This is a cohort, single-center, prospective study that seeks to analyze the circulating tumor DNA (ctDNA) in patients diagnosed with breast cancer, who will undergo neoadjuvant treatment.
- Trial name
- GIRO_ctDNA (NCT05050890)
- Testing
- ctDNA level during neoadjuvant chemotherapy
- Where
- Brazil
- Volunteers
- 38 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Stage III Melanoma, Stage IV Cutaneous Melanoma
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
- Trial name
- NCT05079113
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Primary Central Nervous System Lymphoma (PCNSL)
Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL).
- Trial name
- CLIMB (NCT07842835)
- Testing
- High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Xiaohui Ren
Melanoma (Skin Cancer)
A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
This is a phase II pilot study evaluating the use of circulating tumor DNA (ctDNA) to guide the optimal duration of standard of care immune checkpoint inhibitor (ICI) therapy in patients with unresectable and/or metastatic…
- Trial name
- NCT07830225
- Testing
- A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Colorectal Cancer (CRC)
Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)
This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC…
- Trial name
- RealCHALLENGE (NCT07536113)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Niguarda Hospital
HER2-positive Early-stage Breast Cancer
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design.
- Trial name
- EUREKA (NCT07402473)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Gastric / Gastroesophageal Junction Adenocarcinoma
Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment
For locally advanced gastric adenocarcinoma/esophagogastric junction adenocarcinoma, the currently recommended treatment strategy per clinical guidelines is radical gastrectomy combined with perioperative therapy (including…
- Trial name
- MRD-ATLAS-III (NCT07508956)
- Testing
- Standard neoadjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy, Radical gastrectomy, Standard adjuvant therapy: Chemotherapy/Targeted Therapy/Immunotherapy
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Shanghai Zhongshan Hospital
Epithelial Ovarian Cancer
Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.
Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an…
- Trial name
- ctDNA_EOC (NCT03155451)
- Testing
- methylation markers screening
- Where
- China
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Renal Cancer
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as…
- Trial name
- KIDNEY-PAGER (NCT06145139)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus